Xiaoyu Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoyu Xie has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
- Sicen Wang
School of Pharmacy Health Science Center Xi'an Jiaotong University Xi'an China
24 shared publications Qi Hu
School of Pharmacy Health Science Center Xi'an Jiaotong University Xi'an China
18 shared publicationsLanlan Jia
School of Pharmacy Health Science Center Xi'an Jiaotong University Xi'an China
15 shared publicationsYusi Bu
Xi’an Jiaotong University
15 shared publicationsTingting Zhang
School of Pharmacy Health Science Center Xi'an Jiaotong University Xi'an China
8 shared publicationsXueyan Zhen
School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an 710061, China; Shaanxi Engineering Research Center of Cardiovascular Drugs Screening & Analysis, Xi'an 710061, China
8 shared publications
Latest Publications
- 29 October 2026
- Published by Wiley in Advanced Materials
Biointerface‐Customized Nanomodulators Induce Mitochondria‐Specific Dysfunction to Reprogram Tumor Immunity
Tumor mitochondria regulate cancer progression and immune evasion. However, current therapeutic strategies lack the subcellular precision required to selectively induce immune‐beneficial mitochondrial dysfunction without causing systemic toxicity. Here, we report a biointerface‐customized nanomodulator (C/C‐HP@M2M‐TPP), developed through a biointerface‐engineered strategy (BES), that integrates sequential targeting and controlled activation to induce mitochondria‐specific dysfunction and reprogram tumor immunity. Through a customized biointerface coating, the nanomodulators achieve preferential tumor accumulation and mitochondria‐directed subcellular localization. Co‐delivered calcium ion donors and efflux inhibitors cooperatively induce mitochondrial ion interference and dysfunction, which is further amplified by photothermal activation. This localized mitochondrial interference promotes immunogenic cell death and robust antitumor immune activation, resulting in potent tumor regression in mice. Integrated single‐cell transcriptomic and proteomic analyses further identify mitochondrial disruption as a key mechanistic driver of tumor immune reprogramming. This work establishes biointerface‐customized nanomodulation as a subcellular immunomodulatory therapeutic strategy in vivo.
- 29 October 2026
- Published by Wiley in Advanced Materials
Biointerface‐Customized Nanomodulators Induce Mitochondria‐Specific Dysfunction to Reprogram Tumor Immunity
Tumor mitochondria regulate cancer progression and immune evasion. However, current therapeutic strategies lack the subcellular precision required to selectively induce immune‐beneficial mitochondrial dysfunction without causing systemic toxicity. Here, we report a biointerface‐customized nanomodulator (C/C‐HP@M2M‐TPP), developed through a biointerface‐engineered strategy (BES), that integrates sequential targeting and controlled activation to induce mitochondria‐specific dysfunction and reprogram tumor immunity. Through a customized biointerface coating, the nanomodulators achieve preferential tumor accumulation and mitochondria‐directed subcellular localization. Co‐delivered calcium ion donors and efflux inhibitors cooperatively induce mitochondrial ion interference and dysfunction, which is further amplified by photothermal activation. This localized mitochondrial interference promotes immunogenic cell death and robust antitumor immune activation, resulting in potent tumor regression in mice. Integrated single‐cell transcriptomic and proteomic analyses further identify mitochondrial disruption as a key mechanistic driver of tumor immune reprogramming. This work establishes biointerface‐customized nanomodulation as a subcellular immunomodulatory therapeutic strategy in vivo.
- 9 August 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (33) , 24366-24378
A Light-Controlled DNA Nanoclaw Machine: Integrated Multiplexed Recognition, Spatiotemporally Programmable Therapy, and Real-Time Electrochemical Signaling for Precision Receptor Regulation
Cell membrane receptors are pivotal targets in precise therapeutics, yet their ubiquitous expression across tissues remains a fundamental barrier to achieving cell-specific intervention. To overcome the limitations of conventional monotargeting approaches, we developed a light-gated DNA nanoclaw machine (L-DNM) that integrates high-specificity recognition, spatiotemporally controlled therapy, and real-time monitoring of molecular activation within a unified nanoplatform. The L-DNM employed a multivalent targeting mechanism directed against a triple-marker signature, epithelial cell adhesion molecule (EpCAM), MUC1, and nucleolin (NCL), achieving exceptional targeting accuracy toward MCF-7 human breast cancer cells even in heterogeneous environments. Its novel photocleavable aptamer design ensures that the Met-inhibiting function remains biologically inert until activated by UV irradiation. This strategy enables precise spatiotemporal control over receptor tyrosine kinase (RTK) inhibition with minimal off-target effects. Furthermore, the system couples therapeutic activation with instantaneous electrochemiluminescence (ECL) reporting, transforming molecular recognition events into quantifiable signals with high signal-to-noise ratio in complex matrices. By unifying multiplexed targeting, light-gated activation, and self-reporting capability, the L-DNM platform represents a transformative shift from conventional therapeutics to adaptive, intelligent theranostic systems.
- 9 August 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (33) , 24366-24378
A Light-Controlled DNA Nanoclaw Machine: Integrated Multiplexed Recognition, Spatiotemporally Programmable Therapy, and Real-Time Electrochemical Signaling for Precision Receptor Regulation
Cell membrane receptors are pivotal targets in precise therapeutics, yet their ubiquitous expression across tissues remains a fundamental barrier to achieving cell-specific intervention. To overcome the limitations of conventional monotargeting approaches, we developed a light-gated DNA nanoclaw machine (L-DNM) that integrates high-specificity recognition, spatiotemporally controlled therapy, and real-time monitoring of molecular activation within a unified nanoplatform. The L-DNM employed a multivalent targeting mechanism directed against a triple-marker signature, epithelial cell adhesion molecule (EpCAM), MUC1, and nucleolin (NCL), achieving exceptional targeting accuracy toward MCF-7 human breast cancer cells even in heterogeneous environments. Its novel photocleavable aptamer design ensures that the Met-inhibiting function remains biologically inert until activated by UV irradiation. This strategy enables precise spatiotemporal control over receptor tyrosine kinase (RTK) inhibition with minimal off-target effects. Furthermore, the system couples therapeutic activation with instantaneous electrochemiluminescence (ECL) reporting, transforming molecular recognition events into quantifiable signals with high signal-to-noise ratio in complex matrices. By unifying multiplexed targeting, light-gated activation, and self-reporting capability, the L-DNM platform represents a transformative shift from conventional therapeutics to adaptive, intelligent theranostic systems.
- 28 January 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (15) , e05535
Chemical and Mechanical Synergistic Modulation for Engineered Tumor Cells Enables High‐Performance Biomimetic Detection of Circulating Tumor Cells
Although the idea of employing cell membrane biomimetic technologies for detecting circulating tumor cells (CTCs) promises paradigm‐shifting advances in cancer diagnostics, its wide application is restricted by CTCs phenotypic variations. Current improvements primarily focus on optimizing biomimetic coatings to enhance capture efficiency, but there remains a significant gap between existing strategies and the practical demands of CTCs detection. Herein, a novel method considering the perspective of tumor cell modification was proposed, which involved concurrently modulating cellular chemical and mechanical properties. Specifically, the strategy employed metabolic glycoengineering to selectively remold tumor cells, thereby introducing artificial receptors into the tumor cell membrane. Additionally, Cytochalasin D, a drug that can interfere with the cytoskeleton, was used to alter the mechanical properties of the cell membrane, softening it and thereby significantly enhancing the contact area and adhesion ability between target cells and the substrate surface. To cope with the complex application environment, a visual biomimetic detection system was developed, leveraging the homologous targeting properties of the tumor cell biomimetic layer in combination with advanced colorimetric nanoprobes, enabling highly sensitive and specific detection of engineered CTCs. Overall, this approach adeptly circumvents challenges associated with biomarker bias, offering a robust method for non‐invasive cancer diagnostics.
- 28 January 2026
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (15) , e05535
Chemical and Mechanical Synergistic Modulation for Engineered Tumor Cells Enables High‐Performance Biomimetic Detection of Circulating Tumor Cells
Although the idea of employing cell membrane biomimetic technologies for detecting circulating tumor cells (CTCs) promises paradigm‐shifting advances in cancer diagnostics, its wide application is restricted by CTCs phenotypic variations. Current improvements primarily focus on optimizing biomimetic coatings to enhance capture efficiency, but there remains a significant gap between existing strategies and the practical demands of CTCs detection. Herein, a novel method considering the perspective of tumor cell modification was proposed, which involved concurrently modulating cellular chemical and mechanical properties. Specifically, the strategy employed metabolic glycoengineering to selectively remold tumor cells, thereby introducing artificial receptors into the tumor cell membrane. Additionally, Cytochalasin D, a drug that can interfere with the cytoskeleton, was used to alter the mechanical properties of the cell membrane, softening it and thereby significantly enhancing the contact area and adhesion ability between target cells and the substrate surface. To cope with the complex application environment, a visual biomimetic detection system was developed, leveraging the homologous targeting properties of the tumor cell biomimetic layer in combination with advanced colorimetric nanoprobes, enabling highly sensitive and specific detection of engineered CTCs. Overall, this approach adeptly circumvents challenges associated with biomarker bias, offering a robust method for non‐invasive cancer diagnostics.
- 1 January 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (1) , 1578-1589
Catalytic DNA Circuit-Driven Surface-Enhanced Raman Scattering Amplification Enables Multiplexed Live-Cell Imaging of Receptor Crosstalk and Feedback Regulation
The dysregulation of the hepatocyte growth factor/c-mesenchymal-epithelial transition factor (HGF/c-Met) signaling pathway stimulates an invasive epithelial-mesenchymal transition (EMT) and establishes a pathogenic feedback loop by stimulating vascular endothelial growth factor (VEGF) secretion, creating an urgent need for time-resolved, multiplexed imaging technologies. Current receptor dimerization detection methods have limitations in distinguishing oligomeric states and correlating them with downstream activities. Herein, we developed a catalytic DNA circuit-driven surface-enhanced Raman scattering (SERS) amplification (CDCSA) platform for the comprehensive interrogation of the interconnected HGF/c-Met/VEGF network. In this design, the target-triggered catalytic hairpin assembly guided different reporter probes and enhancer probes to form various plasmonic networks, generating amplified, multichannel SERS outputs. This strategy enabled the independent and simultaneous detection of c-Met homodimerization and the corresponding VEGF secretion while also distinguishing between the c-Met/c-Met homodimers and c-Met/VEGFR heterodimers. Additionally, using three mechanistically distinct inhibitors, the CDCSA platform showed excellent functionality in the time-resolved monitoring of drug-receptor interactions in live cells. Overall, by leveraging the inherent programmability of DNA, this method can be widely adapted to diverse cell membrane biomarkers, offering a versatile approach for analyzing complex signaling networks and accelerating targeted drug discovery.
- 1 January 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (1) , 1578-1589
Catalytic DNA Circuit-Driven Surface-Enhanced Raman Scattering Amplification Enables Multiplexed Live-Cell Imaging of Receptor Crosstalk and Feedback Regulation
The dysregulation of the hepatocyte growth factor/c-mesenchymal-epithelial transition factor (HGF/c-Met) signaling pathway stimulates an invasive epithelial-mesenchymal transition (EMT) and establishes a pathogenic feedback loop by stimulating vascular endothelial growth factor (VEGF) secretion, creating an urgent need for time-resolved, multiplexed imaging technologies. Current receptor dimerization detection methods have limitations in distinguishing oligomeric states and correlating them with downstream activities. Herein, we developed a catalytic DNA circuit-driven surface-enhanced Raman scattering (SERS) amplification (CDCSA) platform for the comprehensive interrogation of the interconnected HGF/c-Met/VEGF network. In this design, the target-triggered catalytic hairpin assembly guided different reporter probes and enhancer probes to form various plasmonic networks, generating amplified, multichannel SERS outputs. This strategy enabled the independent and simultaneous detection of c-Met homodimerization and the corresponding VEGF secretion while also distinguishing between the c-Met/c-Met homodimers and c-Met/VEGFR heterodimers. Additionally, using three mechanistically distinct inhibitors, the CDCSA platform showed excellent functionality in the time-resolved monitoring of drug-receptor interactions in live cells. Overall, by leveraging the inherent programmability of DNA, this method can be widely adapted to diverse cell membrane biomarkers, offering a versatile approach for analyzing complex signaling networks and accelerating targeted drug discovery.
- 16 December 2025
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (3) , 870-877
A cascaded catalytic hairpin 3D DNA walker-assisted dual-targeting biomimetic sensor for intracellular microRNA imaging
Schematic representation of a dual-targeting biomimetic sensor for intracellular miRNA-21 imaging.
- 16 December 2025
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 151 (3) , 870-877
A cascaded catalytic hairpin 3D DNA walker-assisted dual-targeting biomimetic sensor for intracellular microRNA imaging
Schematic representation of a dual-targeting biomimetic sensor for intracellular miRNA-21 imaging.
- Open Access
- 10 December 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 16 (2)
Synergistic cell membrane-coated ECL-DNA biosensor for specificity-enhanced drug lead evaluation
- 10 December 2025
- Published by Elsevier in Journal of Pharmaceutical Analysis
- Vol. 16 (2)
Open AccessSynergistic cell membrane-coated ECL-DNA biosensor for specificity-enhanced drug lead evaluation
Leukocyte Membrane‐Coated Filtrable Micromotors With Selective Distribution of Enzymes for Capturing and Sensing Circulating Tumor Cells
Enzyme‐catalyzed micro/nanomotors exhibit significant promise in drug delivery and sensing due to the exceptional biocompatibility, adaptability, and capacity to employ endogenous fuels. Nevertheless, the flow field generated by the catalytic reaction of enzymes exposed to the outside may considerably impair the recognition ability of surface‐connected functional components, such as aptamers. Here, advantage is taken of cell membrane coating technology to create biomimetic micromotors that selectively distributed glucose oxidase (GOx) and employ aggregation‐induced emission sensing to quickly capture and visualize circulating tumor cells (CTCs). Once the cell membrane selectively filters glucose, the flow field created by GOx is restricted within the intramembrane cavity. This design produces the required driving force while reducing interference on the exterior surface recognition function. By spatially segregating functional components, these biomimetic micromotors achieve CTCs collection in less than a min, enable real‐time in situ detection. The proposed strategy demonstrates the potential of spatially segregated biomimetic micromotors for rapid CTCs enrichment and real‐time sensing, which may inspire further development of multifunctional platforms in liquid biopsy applications.
Leukocyte Membrane‐Coated Filtrable Micromotors With Selective Distribution of Enzymes for Capturing and Sensing Circulating Tumor Cells
Enzyme‐catalyzed micro/nanomotors exhibit significant promise in drug delivery and sensing due to the exceptional biocompatibility, adaptability, and capacity to employ endogenous fuels. Nevertheless, the flow field generated by the catalytic reaction of enzymes exposed to the outside may considerably impair the recognition ability of surface‐connected functional components, such as aptamers. Here, advantage is taken of cell membrane coating technology to create biomimetic micromotors that selectively distributed glucose oxidase (GOx) and employ aggregation‐induced emission sensing to quickly capture and visualize circulating tumor cells (CTCs). Once the cell membrane selectively filters glucose, the flow field created by GOx is restricted within the intramembrane cavity. This design produces the required driving force while reducing interference on the exterior surface recognition function. By spatially segregating functional components, these biomimetic micromotors achieve CTCs collection in less than a min, enable real‐time in situ detection. The proposed strategy demonstrates the potential of spatially segregated biomimetic micromotors for rapid CTCs enrichment and real‐time sensing, which may inspire further development of multifunctional platforms in liquid biopsy applications.
- Open Access
- 23 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (11) , 5988-6000
Electrochemical biosensors with right-side-out-oriented cell membrane coating for the evaluation of AChE inhibitors as potential anti-Alzheimer's disease agents
- 23 September 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 15 (11) , 5988-6000
Open AccessElectrochemical biosensors with right-side-out-oriented cell membrane coating for the evaluation of AChE inhibitors as potential anti-Alzheimer's disease agents
- Open Access
- 17 July 2025
- Published by Springer Nature in Analytical Sciences
- Vol. 41 (10) , 1627-1636
An ultrasensitive sensing strategy based on CRISPR/Cas13a and T7 RNA polymerase amplification for detection of extracellular vesicles
Extracellular vesicles (EVs) are important biomarkers for an early diagnosis of lung cancer. Herein, we proposed an ultrasensitive fluorescent sensing platform for EVs detection, which involves aptamer and streptavidin-modified magnetic nanoparticles (SA-MB) magnetic separation technology as well as T7 RNA polymerase-assisted CRISPR/Cas13a system, which can achieve target recycling signal amplification. In this detection method, biotin-modified CD63 aptamer hybridizes first with the aptamer Blocker (T7 promoter) and then binds to SA-MB. When adding EVs, the CD63 aptamer in CD63 aptamer/Blocker/SA-MB complex captures EVs causing the release of Blocker single chain. Subsequently, large amounts of ssRNAs, which are generated with the assistance of Blocker-initiated T7 RNA polymerase, were recognized by CRISPR/Cas13a and trigger its trans-cleavage report probe (F-Q). Eventually, the report probe labeled with fluorescent dye (FAM) and quench group (BHQ) at both ends was cut to produce fluorescent signal. The designed sensor combined this with a signal amplification strategy based on T7 RNA polymerase and CRISPR/Cas13a to significantly enhance the sensitivity and specificity of EVs detection. The use of magnetic separation technology eliminates interference from complex matrices and improves EVs detection efficiency, while the introduction of T7 RNA polymerase and CRISPR/Cas13a enables multiple amplifications of the sensor signals, and enhancing the accuracy and sensitivity of the method. Ultimately, the combination of multiple amplification reactions resulted in a detection limit (LOD) for EVs as low as 60 particles/mL (approximately 1 zmol/L). In addition, this detection method can specifically distinguish EVs from other confounding substances and efficiently detect plasma EVs from lung cancer and healthy individuals in actual samples. Indicating this sensing platform is a valuable tool for early lung cancer detection. Graphical abstract
- 17 July 2025
- Published by Springer Nature in Analytical Sciences
- Vol. 41 (10) , 1627-1636
Open AccessAn ultrasensitive sensing strategy based on CRISPR/Cas13a and T7 RNA polymerase amplification for detection of extracellular vesicles
Extracellular vesicles (EVs) are important biomarkers for an early diagnosis of lung cancer. Herein, we proposed an ultrasensitive fluorescent sensing platform for EVs detection, which involves aptamer and streptavidin-modified magnetic nanoparticles (SA-MB) magnetic separation technology as well as T7 RNA polymerase-assisted CRISPR/Cas13a system, which can achieve target recycling signal amplification. In this detection method, biotin-modified CD63 aptamer hybridizes first with the aptamer Blocker (T7 promoter) and then binds to SA-MB. When adding EVs, the CD63 aptamer in CD63 aptamer/Blocker/SA-MB complex captures EVs causing the release of Blocker single chain. Subsequently, large amounts of ssRNAs, which are generated with the assistance of Blocker-initiated T7 RNA polymerase, were recognized by CRISPR/Cas13a and trigger its trans-cleavage report probe (F-Q). Eventually, the report probe labeled with fluorescent dye (FAM) and quench group (BHQ) at both ends was cut to produce fluorescent signal. The designed sensor combined this with a signal amplification strategy based on T7 RNA polymerase and CRISPR/Cas13a to significantly enhance the sensitivity and specificity of EVs detection. The use of magnetic separation technology eliminates interference from complex matrices and improves EVs detection efficiency, while the introduction of T7 RNA polymerase and CRISPR/Cas13a enables multiple amplifications of the sensor signals, and enhancing the accuracy and sensitivity of the method. Ultimately, the combination of multiple amplification reactions resulted in a detection limit (LOD) for EVs as low as 60 particles/mL (approximately 1 zmol/L). In addition, this detection method can specifically distinguish EVs from other confounding substances and efficiently detect plasma EVs from lung cancer and healthy individuals in actual samples. Indicating this sensing platform is a valuable tool for early lung cancer detection. Graphical abstract
- 26 May 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (22) , 11745-11753
Assembly of DNA Networks on the Cell Membrane Enables Confined Detection of MMP-9 Secretion and Evaluation of Drug Efficacy
Proteases secreted by tumor cells have been employed as potential biomarkers for the early assessment of tumor metastasis risk. However, in situ monitoring of their secretion at the single-cell level remains a challenge due to their low abundance and diffusion into complex environments. Despite significant advancements in utilizing DNA as a versatile scaffold for constructing dynamic sensing systems due to its programmability and design flexibility, the spatial control of molecular sensing and imaging functions within living cells is particularly challenging. Herein, we developed a DNA network (termed cAME) by introducing acrylamide copolymers combined with aptamer technology to enable a confined detection of single-cell matrix metalloproteinase-9 (MMP-9) secretion for the assessment of tumor cell invasiveness and drug efficacy evaluation. The cAME was established from a combination of a detecting DNA copolymer (MDDC) containing an MMP-9 responsive aptamer sensor, an encapsulating DNA copolymer (EDC), and a cell membrane anchoring module (chol-A). By monitoring changes in fluorescence signals, real-time detection of MMP-9 activity in individual cells could be achieved. Using various cancer cell lines as models, the feasibility of the proposed confined detection strategy in assessing the heterogeneity of MMP-9 secretion among different subtypes of breast cancer cells was validated. Furthermore, by employing two drugs as models, the application value of the proposed confined detection strategy in rapid and sensitive evaluation of drug efficacy was demonstrated. This strategy contributed to the assessment of tumor metastasis risk while also providing new insights for evaluating the efficacy of antitumor drugs.
- 26 May 2025
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (22) , 11745-11753
Assembly of DNA Networks on the Cell Membrane Enables Confined Detection of MMP-9 Secretion and Evaluation of Drug Efficacy
Proteases secreted by tumor cells have been employed as potential biomarkers for the early assessment of tumor metastasis risk. However, in situ monitoring of their secretion at the single-cell level remains a challenge due to their low abundance and diffusion into complex environments. Despite significant advancements in utilizing DNA as a versatile scaffold for constructing dynamic sensing systems due to its programmability and design flexibility, the spatial control of molecular sensing and imaging functions within living cells is particularly challenging. Herein, we developed a DNA network (termed cAME) by introducing acrylamide copolymers combined with aptamer technology to enable a confined detection of single-cell matrix metalloproteinase-9 (MMP-9) secretion for the assessment of tumor cell invasiveness and drug efficacy evaluation. The cAME was established from a combination of a detecting DNA copolymer (MDDC) containing an MMP-9 responsive aptamer sensor, an encapsulating DNA copolymer (EDC), and a cell membrane anchoring module (chol-A). By monitoring changes in fluorescence signals, real-time detection of MMP-9 activity in individual cells could be achieved. Using various cancer cell lines as models, the feasibility of the proposed confined detection strategy in assessing the heterogeneity of MMP-9 secretion among different subtypes of breast cancer cells was validated. Furthermore, by employing two drugs as models, the application value of the proposed confined detection strategy in rapid and sensitive evaluation of drug efficacy was demonstrated. This strategy contributed to the assessment of tumor metastasis risk while also providing new insights for evaluating the efficacy of antitumor drugs.